The use of the antidepressant amitriptyline in patients with lung cancer


(57) Abstract:

The invention relates to medicine, in particular to Oncology, and concerns the application of the antidepressant amitriptyline as a means of having antiallergic action, for the correction of allergic status in patients with lung cancer. The invention eliminates the appointment of two drugs (anti-allergic and antidepressant) and thereby avoid polipragmazie, to improve the quality of life of patients, to create a positive pharmacoeconomic effect.

The invention relates to medicine, namely to clinical pharmacology.

The purpose of the invention is the use of amitriptyline for anti-allergic therapy of lung cancer patients.

For the treatment and prevention of paraneoplastic allergies currently use antihistamines (blockers H1receptors), drugs, inhibiting the release and activity of histamine and other mediators of Allergy (stabilizers of membranes); antiserotonin, anti-srs-A (slow reacting substance of Appalachia) agents; glucocorticoids; immunosuppressants (Great medical encyclopedia. - M., 1974.-T. 1. - S. 284-286).

Antide the application of tricyclic antidepressant amitriptyline for correction of allergic status of lung cancer patients.

Amitriptyline is one of the main representatives of tricyclic antidepressants. Timolepticheskoe combined amitriptyline with pronounced sedative effect. The drug is relatively widely used in somatic medicine with depression and neuroticism (Mashkovsky M. D. Medicines. - Kharkov, 1997. - T. 1. - S. 98-99).

Amitriptyline was administered inside of 0.0125 g 2 times a day. Control study of allergic status according to the reaction of degranulation of basophils was performed before and after 7 days of treatment with amitriptyline.

According to reaction degranulation of basophils (Timashev E. D., Cavatina A. I.// lab.Affairs. - 1969. 3. - S. 135-138) amitriptyline had a pronounced positive effect on patients. Spontaneous degranulation of basophils in patients with lung cancer (5,40,14) was significantly increased (P<0.05) as compared with healthy (2,40,1).

On the background of therapy with amitriptyline detected a certain regularity in the dynamics of spontaneous degranulation of basophils, which showed reliable weakening of this reaction at the end of the drug treatment (2,70,15; P<0,05).

The use of the antidepressant amitriptyline in patients with lung cancer as a means of having antiallergic action, for the correction of allergic status.


Same patents:

The invention relates to medicine and relates to methods for obtaining protein hydrolysate suppressive regulation of allergic reactions, methods of prevention or treatment of allergies

The invention relates to new ascomycin General formula I, where Y represents a phenylene; Z is selected from carboxyl and physiologically hydrolyzable of oxycarbonyl or alkyl, CNS, alkylamino or dialkylamino bearing from 1 to 4 carboxyl or physiologically hydrolyzable oxycarbonyl group; Q is O or S; R1Is H, alkyl or aryl; R2is hydrogen or hydroxyl; R3is methyl, ethyl, propyl or allyl; R4is hydroxyl or alkoxyl; R5-oxoprop or (H, OH), R6- oxoprop, H, HE H, alkoxyl); n is an integer 1 or 2, in free form or in the form of a pharmaceutically acceptable salt

The invention relates to previously unknown compounds, useful in medical and veterinary practice, to their pharmaceutically acceptable salts and biopremier derivatives, to methods for obtaining data of new compounds, to pharmaceutical compositions containing these new compounds, to a single dosage forms of these compositions and to methods of treating patients using these compositions and dosage forms

The invention relates to medicine, specifically to medicines, exhibiting anti-allergic, anti-asthma and anti-inflammatory effect

The invention relates to the field of medicine and is suitable for the treatment of seasonal and perennial allergic rhinitis, conjunctivitis, hay fever, urticaria, including chronic idiopathic urticaria, angioedema, psevdoallergicakie reactions caused by the release of histamine, itching dermatoses, allergic reactions to insect bites and itching of various etiology

The invention relates to cyclopentapeptide formula (I):

cyclo (A-B-C-E-F-(D)-Ala)

in which A, B, C, E and F, independently of one another, may be the same or different and represent a residue of a natural amino acid except cysteine (Cys) and tryptophan (Trp), and accordingly can be an alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), Proline (Pro), serine (Ser), tryptophan (Thr), tyrosine (Tyr) or valine (Val), as well as their physiologically compatible salts

The invention relates to a dosage form for oral administration of fast-acting composition for modulating sexual response and/or treatment of impotence
The invention relates to medicine, namely to ophthalmology, and relates to a composition for pain relief and reduce inflammation

-adrenergic agonist as an antagonist of substance p" target="_blank">

The invention relates to medicine, namely to dermatology, and concerns the use of at least one-adrenergic agonist in cosmetic compositions as an antagonist of substance P for the treatment of diseases associated with excessive synthesis and/or release of substance P

The invention relates to the chemistry of aminoalcohols, in particular, to an improved process for the preparation of tramadol - 2-dimethyl aminomethyl-1-(3-methoxyphenyl)cyclohexanol

The invention relates to liposomal compositions containing as the active ingredient selegiline (-)-(N-dimethyl-N-(2-propylpentyl) and/or its salt

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention describes compound of the formula (I):

as a free form or salt wherein Ar means group of the formula (II):

wherein R1 means hydrogen atom or hydroxy-group; R2 and R3 each means independently of one another hydrogen atom or (C1-C4)-alkyl; R4, R5, R6 and R7 each means independently of one another hydrogen atom, (C1-C4)-alkoxy-group, (C1-C4)-alkyl or (C1-C4)-alkyl substituted with (C1-C4)-alkoxy-group; or R5 and R6 in common with carbon atoms to which they are joined mean 6-membered cycloaliphatic ring or 6-membered heterocyclic ring comprising two oxygen atoms; R8 means -NHR13 wherein R13 means hydrogen atom, (C1-C4)-alkyl or -COR14 wherein R14 means hydrogen atom; or R13 means -SO2R17 wherein R17 means (C1-C4)-alkyl; R9 means hydrogen atom; or R8 means -NHR18 wherein -NHR18 and R9 in common with carbon atoms to which they are joined mean 6-membered heterocycle; R10 means -OH; X means (C1-C4)-alkyl; Y means carbon atom; n = 1 or 2; p = 1; q = 1; r = 0 or 1. Also, invention describes pharmaceutical composition based on compound of the formula (I), a method for preparing compound of the formula (I) and intermediate compound that is used in the method for preparing. Compounds elicit the positive stimulating effect of β2-adrenoceptor.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

13 cl, 3 tbl, 35 ex

FIELD: medicine, neurology.

SUBSTANCE: the present innovation describes arylalkylamines that specifically affect certain types of receptor-operated Ca2+-canals, their application and pharmaceutical compositions for treating neurological disorders or diseases.

EFFECT: higher efficiency.

55 cl, 29 ex, 11 tbl

FIELD: medicine, dermatology.

SUBSTANCE: invention proposes an anti-infectious preparation comprising the combination of active substances with topical and systemic antifungal agents and a water-insoluble film-forming agent. The systemic antifungal agent is taken among the group including intraconazole, terbinafine and fluconazole or their salts. The topical antifungal agent is taken among the group including ciclopirox, 6-(2,4,4-trimethylpentyl)-1-hydroxy-4-methyl-2(1H)-pyridone, amorolfine and butenafine or their salts. The preparation is used as lacquer for nails in therapy of onychomycosis. The lacquer preparation provides high concentration of systemic antifungal agents in nails after its topical applying. The significant advantage of the preparation involves short time in treatment of anychomycosis.

EFFECT: enhanced effectiveness and valuable medicinal properties of preparation.

6 cl, 6 ex

FIELD: medicine, gastroenterology, surgery, endoscopy.

SUBSTANCE: method involves injection of adrenaline hydrochloride 0.01% solution that is administrated in the amount 10 ml and injection is carried out from 4-6 points in the dose 1.6-2.5 ml per a point, and dalargin in the dose 1 mg diluted in 2 ml of physiological solution, and the preparation is injected from 4 points in the dose 0.5 ml per a point. These medicinal agents are administrated into submucosa periulcerogenic zone wherein the preparation "TakhoKomb" is used for application that is pressed to the bottom of ulcer defect for 2 min, not less. Invention promotes to diminish the amount of bleeding relapses in early post-hemorrhagic period due to the combined effect of "TakhoKomb", adrenaline and dalargin. Invention can be used in carrying out the endoscopic hemostasis in bleeding-complicated chronic gastroduodenal ulcers.

EFFECT: improved method for hemostasis.

2 ex

FIELD: medicine, infectious diseases, psychotherapy.

SUBSTANCE: method involves antiviral therapy, immune correction with thymus hormones and interferon inductors. Since the first day the relapse symptom method involves prescription of antiox+ (1 capsule per a day) and detox+ (1 capsule, 2 times per a day) for 30 days, profluzak (20 mg, 3 times per a day for 5 days) and then in the dose 20 mg, 1 time per a day for 20 days. Derinate is prescribed topically as installation into urethra in the dose 3-5 ml or with tampon into vagina and with simultaneous prescription of microenemas in the dose 10-40 ml for 10 days. Since 10-14 day in exacerbation period in the proliferative stage of an antiherpetic immune response derinate is prescribed by intramuscular injections in the dose 5 ml, 1 time in a day, 10 injections in total number. Then since 6-th day of exacerbation and intake of profluzak psychotherapy seances are carried out. The first seance of rational psychotherapy involves explanation to a patient in available form mechanism of the disease, the necessity of prolonged treatment and motivation for treatment is enhanced by suggestion. The second psychotherapy seance involves neurolinguistic programming wherein a patient colorful and detailed description of desirable function when he imagines achievement of the desire result, and positive emotional and vegetative symptoms are notes and the conditional-reflect association is formed by tactile contact. Under psychotherapist control a patient imagines "part of person" responsible for achievement of the desire result the patient attention is accented for the desire result and arisen physiological responses are fixed by using tactile contact. Also, new behavior methods are proposed to take for a patient that are directed for achievement of the desire result - avoiding sexual contacts during exacerbation of genital herpes in one of partner and during every month hormonal cycles, avoiding stress situations, and in case of each stress situation significant for patient profluzak has to be intake in a single dose 40 mg, using a condom in sexual contact in the exacerbation period. Patient analyzes the proposed new behavior methods that help avoiding relapses, provide good state of health, promotes to recovery process of genitals recovery and selects at least three the most rationally available for him behavior methods. In the case of the positive response that is controlled by physiological symptoms the result is fixed by tactile contact. The third seance involves the suggestive psychotherapy directed for fixing the attained result. The suggestive therapy seance is carried out once per a week for 6 months. Method provides declining the treatment time, to reduce relapse frequency of genital herpes and to recover the emotional state of patient.

EFFECT: improved treatment method.

2 cl, 3 tbl, 1 ex

FIELD: medicine, phthisiology, in particular chronotherapy of patients suffering from disseminated pulmonary tuberculosis with β2-agonists.

SUBSTANCE: two doses β2-agonists, namely salbutamol and fenoterol are administered at 11, 17 and 23 o'clock.

EFFECT: improvement of external respiration in early period; preventing severe blockages of bronchial tree; improvement of patient quality of life.